Life Sciences Tools and Services
Company Overview of MerLion Pharmaceuticals Pte. Ltd.
MerLion Pharmaceuticals Pte. Ltd., a drug discovery and development company, engages in the research and development of natural products. It operates through two business units, MerLion Research and MerLion Development. The MerLion Research unit is a contract services business, which provides access to natural product collections by offering sample/extract supply services, extract profiling and standardization, assay development, throughput screening, compound purification and structural identification, biocatalyst isolation, and strain improvement. The MerLion Development unit is progressing finafloxacin, a differentiated antibacterial candidate through phase II clinical trials, which is ta...
1 Science Park Road
05-01 The Capricorn
Singapore Science Park II
Founded in 2002
Key Executives for MerLion Pharmaceuticals Pte. Ltd.
Managing Director of MerLion Pharmaceuticals GmbH
Compensation as of Fiscal Year 2016.
MerLion Pharmaceuticals Pte. Ltd. Key Developments
MerLion Announces FDA Approval of Finafloxacin Otic Suspension
Feb 11 15
MerLion Pharmaceuticals announced that an otic suspension of finafloxacin has been approved by the FDA to treat acute otitis externa, commonly known as swimmer's ear, caused by Pseudomonas aeruginosa and Staphylococcus aureus. Finafloxacin was licensed by MerLion to a major North American partner in 2010 for use in North America for otic (ear) infections. MerLion retains the rights to intravenous and oral formulations of finafloxacin for all other indications and recently announced positive results from a phase 2 trial conducted in Europe treating around 200 patients hospitalized with complicated urinary tract infections. The results from this study demonstrated positive outcomes at all primary and all secondary endpoints; with patients treated once daily for five days with finafloxacin seeing higher, more rapid and sustained level of microbiological eradication and improved clinical outcomes compared to those treated with the current standard of care (ciprofloxacin taken twice daily for 10 days).
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries